Answers are grounded in this paper and cite their sources.
Case report reveals recurrent generalized seizures in a young man exposed to MDMB-FUBINACA via vaping, highlighting severe toxicity risks of mislabeled cannabis products.
Novel psychoactive substances (NPS) consist of multiple pharmacological classes of compounds, including synthetic cannabinoids (SC). Multiple NPS emerge each year on the recreational market, and new chemical structures are continuously identified. The short- and long-term clinical effects of NPS are often poorly characterized. The rapid evolution of NPS challenges routine toxicological screening, which frequently fails to detect many of the compounds. MDMB-FUBINACA, an indazole carboxamide SC, is a potent agonist of the cannabinoid receptors CB1 and CB2. MDMB-FUBINACA has been associated with a wide range of severe, life-threatening effects and even fatal outcomes, as was the case in a Russian outbreak in 2014. Due to widespread legislative regulations in 2015, MDMB-FUBINACA was reported less frequently after 2017, but reemerged in 2024 on the recreational market. We describe a case involving a young man who experienced recurrent generalized seizures as a consequence of inadvertent exposure to MDMB-FUBINACA from vaping an e-liquid labelled to contain “THC”. The analytical findings were consistent with exposure to MDMB-FUBINACA as determined by liquid chromatography-high resolution mass spectrometry. The case report underlines the risk of vaping easily available and often mislabeled cannabis products, as there is a risk for exposure to high-risk substances, including SCs such as MDMB-FUBINACA.
No takes yet. Share an insight, caveat, or question.
Said et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: